Successful management of dengue in renal transplant recipients: A retrospective cohort from a single center

Meshram, Hari Shankar; Kute, Vivek B.; Patel, Himanshu V.; Banerjee, Subho; Chauhan, Sanshriti; Desai, Sudeep

doi:10.1111/ctr.14332

Cited by 1 publication

(1 citation statement)

References 43 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our center, a previous study of invasive fungal infection reported 25% graft loss. 28 Similarly dengue cohort 29 from our center reported 6.4% acute rejection and 6.4% graft loss. Our preliminary report hence do not suggest any increased risk of graft loss or rejection compared to other infections…”

Section: Discussionmentioning

confidence: 91%

Long‐term follow‐up of SARS‐CoV‐2 recovered renal transplant recipients: A single‐center experience from India

Chauhan

Meshram

Kute

et al. 2021

Transplant Infectious Dis

Self Cite

View full text Add to dashboard Cite

Introduction Follow‐up studies of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in kidney transplant recipients (KTR) are scarcely reported. Methods We studied 142 hospitalized KTR for a median (interquartile range) follow‐up of 9 (8–11) months who recovered from SARS‐CoV‐2 during May 2020 to Dec 2020. The outcomes were to assess persistent symptoms post‐discharge; EuroQoL visual analogue score (EQ‐VAS); EuroQoL 5‐dimension score (E5‐QD‐5L) score and modified medical research dyspnea score (mMRC) at 1 month, 3‐month, and beyond 6 months. Graft outcome was also analyzed. Results The age of the cohort was 43 (34–69) years and COVID‐19 severity ranged from asymptomatic (4%), mild (50%), moderate (35%) to severe (12%). The most common persistent symptom was fatigue which significantly decreased in the follow‐up ( n = 45 [32.3] vs. 10 [7.4] vs. 4 [2.9]; p ‐value = 0.001) at 1‐month, 3‐month, and beyond 6 months respectively. Decrement in the mean (standard deviation) EQ‐VAS score from baseline was also improved (28.6 [13] vs. 10.4 [12.5] vs. 7.5 [12.0]; p ‐value = 0.012). There was significant improvement in all EQ‐5D‐5L scores in follow‐up. There was no deterioration in mMRC scores during the follow‐up ( n = 4, 3% vs. 7, 5% vs. 3, 2%; p ‐value = 0.86). Cases requiring oxygen had significantly poorer overall scores initially, but there was no difference at 6 months. All 10 graft losses had oxygen requirement and chronic graft dysfunction at baseline. Conclusion Our initial assessment reports significant improvement in the quality of life in follow‐up. The majority recovered from allograft dysfunction. Further research is warranted to study the full spectrum of follow‐up.

show abstract

Section: Discussionmentioning

confidence: 91%